Alvotech, battling AbbVie over its Humira biosim, raises $450M and tees up Nasdaq debut
Alvotech, the biosim specialist locked in a legal battle over AbbVie's sales Goliath Humira, is revving up for its debut on the Nasdaq.
The Icelandic company is join...